Based on the available search results, I can provide you with the 6-12 month target price projections for Summit Therapeutics (SMMT).
Multiple analyst forecasts indicate a consensus bullish outlook for SMMT stock over the next 6-12 months. The average price target across analysts is approximately $36.67-$38.50, with a range between $30.00 (minimum) and $44.00 (maximum)[1][4]. This represents a potential upside of about 48.94% from current levels[4].
Specifically, according to TradingView data, 9 analysts offering 1-year price forecasts have an average target of $36.56[2]. Public.com reports that 15 analysts have given Summit Therapeutics a consensus “Buy” rating with a 2025 price prediction of $30.87[3].
It’s worth noting that while most analyst projections are bullish, Gov.Capital’s prediction system offers a somewhat different outlook, forecasting a price of $21.785 (11.78% increase) after one year, though their 6-month forecast still shows a substantial 31.21% expected increase[5].
The strong buy consensus from multiple sources suggests positive sentiment around Summit Therapeutics’ future performance, likely related to their pipeline developments, though I cannot specifically comment on the press release mentioned in your query as it was not included in the search results.